AMENDMENTS TO THE CLAIMS

Claims 1-27 (Canceled)

Claim 28 (Previously presented): A peptide dimer that inhibits CTL-mediated cytotoxicity, wherein the dimer consists of an α-β, β-β, or β-α dimer,

wherein α is R E aa^{77} L R aa^{80-83} Y (I) (SEQ ID NO:38),

β is Y aa^{83-80} R L aa^{77} E R (II) (SEQ ID NO:39),

or a N-terminal acylated and/or C-terminal amidated or esterified form of said α or β;

wherein aa^{77} is D, S or N;

aa^{80} is I or N;

aa^{81} is A or L;

aa^{82} is R or L; and

aa^{83} is G or R.

Claim 29 (Previously presented): The peptide of claim 28 wherein aa^{80} is I.

Claim 30 (Previously presented): The peptide of claim 28 wherein aa^{82} is L.

Claim 31 (Previously presented): The peptide of claim 28 wherein aa^{83} is R.

Claim 32 (Previously presented): The peptide of claim 28 wherein at least one of the amino acids is the D-isomer.

Claim 33 (Previously presented): The peptide of claim 32 wherein all of the amino acids are the D-isomer.

Claim 34 (Previously presented): The peptide of claim 28 which is YRLAIRLNERRENLRIALRY (SEQ ID NO:26) or YRLAIRLNERYRLAIRLNER (SEQ ID NO:31).

Claim 35 (Currently amended): The ~~peptide-type compound~~ peptide of claim 28 which is a peptide and wherein all the amino acid residues in the peptide are gene-encoded.

Claim 36 (Previously presented): A composition comprising the peptide of claim 28 and a subtherapeutic dosage of an immunosuppressant, together in an amount sufficient to inhibit transplant rejection in a mammal, in a physiologically acceptable medium.

Claim 37 (Previously presented): A method for extending the period of acceptance by a recipient of a transplant from an allogeneic or xenogeneic MHC donor, said method comprising:

administering to said donor in accordance with a therapeutically effective regimen and in an amount effective to extend the period of acceptance of the transplant, the peptide of claim 28;

whereby the period of acceptance of the transplant is extended.

Claim 38 (Previously presented): The method of claim 37, wherein the peptide is administered in combination with a subtherapeutic dosage of an immunosuppressant, and the period of acceptance is extended as compared to the period which would have resulted from the administering of the immunosuppressant as the subtherapeutic dosage in the absence of the peptide.

Claim 39 (Currently amended): A peptide dimer that inhibits CTL-mediated cytotoxicity wherein the peptide dimer ~~consists essentially of~~ is RIALRYYRLAIR (SEQ ID NO:40), YRLAIRRIALRY (SEQ ID NO:36), or YRLLIRYRLAIR (SEQ ID NO:42).

Claim 40 (Previously presented): The peptide dimer of claim 39 which is YRLAIRRIALRY (SEQ ID NO:36).

Claim 41 (canceled)